Chongqing Lummy Unit Gains Approval for Finerenone API Market Launch

Stock News

Yesterday

Chongqing Lummy Pharmaceutical Co.,Ltd. (300006.SZ) has announced that its wholly-owned subsidiary, Chongqing Lummy Longyu Pharmaceutical Co., Ltd., recently received the Chemical Drug Active Pharmaceutical Ingredient Market Launch Approval Notice for Finerenone, officially issued by the National Medical Products Administration.

Finerenone is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist. Its formulation is indicated for the treatment of adult patients with chronic kidney disease associated with type 2 diabetes.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/news/1101938576"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1101938576\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1101938576?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-14 16:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101938576","market":"fut","top_or_hot":-1,"title":"Chongqing Lummy Unit Gains Approval for Finerenone API Market Launch","media":"Stock News","content":"<p><b>Chongqing Lummy Pharmaceutical Co.,Ltd.</b> (300006.SZ) has announced that its wholly-owned subsidiary, Chongqing Lummy Longyu Pharmaceutical Co., Ltd., recently received the Chemical Drug Active Pharmaceutical Ingredient Market Launch Approval Notice for Finerenone, officially issued by the National Medical Products Administration.<br><br>Finerenone is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist. Its formulation is indicated for the treatment of adult patients with chronic kidney disease associated with type 2 diabetes.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chongqing Lummy Unit Gains Approval for Finerenone API Market Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChongqing Lummy Unit Gains Approval for Finerenone API Market Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-14 16:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Chongqing Lummy Pharmaceutical Co.,Ltd.</b> (300006.SZ) has announced that its wholly-owned subsidiary, Chongqing Lummy Longyu Pharmaceutical Co., Ltd., recently received the Chemical Drug Active Pharmaceutical Ingredient Market Launch Approval Notice for Finerenone, officially issued by the National Medical Products Administration.<br><br>Finerenone is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist. Its formulation is indicated for the treatment of adult patients with chronic kidney disease associated with type 2 diabetes.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0070","symbol_name":"员工持股","start_time":0,"source_url":"","article_id":"1101938576","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101938576","pubTimestamp":1789374147,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Chongqing Lummy Pharmaceutical Co.,Ltd. (300006.SZ) has announced that its wholly-owned subsidiary, Chongqing Lummy Longyu Pharmaceutical Co., Ltd., recently received the Chemical Drug Active...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300006":"莱美药业","BK0070":"员工持股","BK0239":"医药制造","IPOS":"Renaissance International IPO ETF"},"translate_title":"重庆 Lummy 装置获得 Finerenone API 上市批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300006":1,"IPOS":1},"content_text":"Chongqing Lummy Pharmaceutical Co.,Ltd. (300006.SZ) has announced that its wholly-owned subsidiary, Chongqing Lummy Longyu Pharmaceutical Co., Ltd., recently received the Chemical Drug Active Pharmaceutical Ingredient Market Launch Approval Notice for Finerenone, officially issued by the National Medical Products Administration.Finerenone is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist. Its formulation is indicated for the treatment of adult patients with chronic kidney disease associated with type 2 diabetes.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}